Exhibit 99.1 Irvine, California, May 6, 2025 - Masimo Corporation (Nasdaq: MASI) today announced its financial results for the first quarter ended March 29, 2025. First Quarter 2025 Results From Continuing Operations : (1) First Quarter 2025 Results From Discontinued Operations : (2) Masimo Reports First Quarter 2025 Results ■ GAAP loss from discontinued operations, net of tax was ($218) million, which included an impairment of intangibles of $295 million for the non-healthcare consumer business. Katie Szym ...

Core Insights - The Medical sector is expected to see double-digit earnings growth in 2025, driven by strong product revenues and growing demand, despite geopolitical issues and a stronger U.S. dollar impacting costs for domestic companies [1][4]. Earnings Overview - As of April 30, 45% of Medical sector companies, representing 57.9% of the sector's market capitalization, reported earnings, with 66.7% exceeding earnings and revenue estimates. Year-over-year earnings increased by 85.2% on a revenue increase of 70.4% [3]. - First-quarter 2025 earnings for the Medical sector are projected to improve by 40% with an 8.3% sales increase, compared to 13.4% earnings growth and 9.4% revenue growth in the previous quarter [4]. MedTech Trends - The adoption of generative AI and digital therapies is enhancing patient-friendly services, driven by an aging population and increased healthcare awareness, creating new revenue opportunities for MedTech companies [5]. - Despite positive trends, challenges such as macroeconomic uncertainties, supply-chain disruptions, and labor shortages may have impacted the sector's performance [6]. Company-Specific Insights - **Fresenius Medical Care**: Expected to report revenues of $5.25 billion with an EPS estimate of 43 cents, benefiting from the FME25 transformation program, but facing challenges from high U.S. dialysis patient mortality and labor cost inflation [8][9]. - **Masimo Corporation**: Anticipated to report revenues of $367.3 million and an EPS of $1.24, supported by strong performance across major product platforms and manufacturing efficiencies [10][11]. - **Clover Health**: Projected to report revenues of $476.9 million with a loss per share estimate of 7 cents, driven by strong member retention and growth in Medicare Advantage membership, though facing near-term margin pressures due to rapid expansion [12][13].

Core Insights - Masimo (MASI) has consistently surpassed earnings estimates, averaging a beat of 18.74% over the last two quarters [1][5] - In the most recent quarter, Masimo reported earnings of $1.80 per share, exceeding the expected $1.49 per share by 20.81% [2] - The previous quarter also saw Masimo outperforming estimates, reporting $0.98 per share against an expectation of $0.84 per share, a surprise of 16.67% [2] Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Masimo, with a positive Zacks Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5][8] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6] - Masimo currently holds an Earnings ESP of +0.64%, suggesting analysts are optimistic about the company's earnings prospects [8] Zacks Rank and Earnings ESP - The combination of a positive Earnings ESP and a Zacks Rank 1 (Strong Buy) indicates a high probability of another earnings beat for Masimo [8] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7] - A negative Earnings ESP does not necessarily indicate an earnings miss, but it reduces the predictive power of the metric [8]

Company Overview - Masimo Corporation (MASI) is positioned as an intriguing investment choice within the Medical - Instruments sector, supported by solid earnings estimate revisions [1][3]. - The company has experienced a positive shift in earnings estimates, indicating a more bullish outlook from analysts regarding its short and long-term prospects [3]. Industry Context - The Medical - Instruments industry currently holds a Zacks Industry Rank of 66 out of over 250 industries, suggesting a favorable position compared to other sectors [2]. - The industry is experiencing broad trends that are positively impacting securities across the board, indicating a rising tide effect [2]. Earnings Estimates - Over the past month, Masimo's current quarter earnings estimates have increased from $1.17 per share to $1.24 per share, while current year estimates have risen from $5.07 per share to $5.28 per share [4]. - These revisions have contributed to Masimo earning a Zacks Rank 1 (Strong Buy), highlighting the company's strong market position [4]. Investment Consideration - Given the strong performance of the industry and the positive earnings revisions, Masimo is recommended as a compelling option for investors seeking opportunities in a robust industry segment [5].

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? ...

Economic Overview - Investors are concerned about the potential economic downturn due to new tariffs imposed by Trump, with Goldman Sachs raising its recession forecast from 20% to 35% [1][2] - Economists warn that these tariffs could lead to increased costs for businesses, a slowdown in hiring, and wage growth, prompting Wall Street firms to lower GDP growth projections [2] Medical Device Industry Outlook - The medical device industry is viewed as a stable investment during market volatility, with a promising long-term outlook despite short-term challenges such as tariffs and cost escalations [3] - Advancements in AI and predictive analytics are revolutionizing the medical device industry, enhancing diagnostics, patient monitoring, and personalized treatment [4] Company Highlights Masimo (MASI) - Masimo specializes in non-invasive patient monitoring systems and is benefiting from focused R&D efforts, with notable technologies like Measure-through Motion and Low Perfusion pulse oximetry [7] - MASI shares have increased by 1.4% year to date, outperforming the broader market, and the company is expected to report earnings growth of 20% in 2025 [8] Boston Scientific (BSX) - Boston Scientific is experiencing strength across its MedSurg and Cardiovascular lines, with strong demand and contributions from acquisitions driving growth [10] - BSX shares have risen 13.3% year to date, and the company is expected to report earnings growth of 13.6% in 2025 [12] Hims & Hers Health (HIMS) - Hims & Hers Health targets a $360 million U.S. total addressable market, focusing on mental health, weight loss, and dermatology, with over 2 million subscribers driving recurring revenues [15] - HIMS shares have surged 28.4% year to date, with an expected earnings growth of 133.3% in 2025 [16]

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying strong candidates is challenging due to inherent risks and volatility [1] Group 1: Growth Stock Identification - The Zacks Growth Style Score aids in identifying promising growth stocks by analyzing real growth prospects beyond traditional metrics [2] - Masimo (MASI) is currently highlighted as a recommended growth stock, possessing a favorable Growth Score and a top Zacks Rank [2] Group 2: Earnings Growth - Earnings growth is a critical factor for growth investors, with double-digit growth seen as a strong indicator of future stock price gains [3] - Masimo's projected EPS growth for this year is 20%, significantly higher than the industry average of 12.6% [4] Group 3: Cash Flow Growth - High cash flow growth is essential for growth-oriented companies, allowing them to fund new projects without relying on external financing [5] - Masimo's year-over-year cash flow growth stands at 13%, compared to an industry average of -0.2% [5] - The company's annualized cash flow growth rate over the past 3-5 years is 10.7%, exceeding the industry average of 6.5% [6] Group 4: Earnings Estimate Revisions - Positive trends in earnings estimate revisions correlate strongly with stock price movements [7] - Masimo has experienced upward revisions in current-year earnings estimates, with a 4.2% increase in the Zacks Consensus Estimate over the past month [7] Group 5: Overall Assessment - Masimo's combination of a Zacks Rank 1 and a Growth Score of A positions it as a potential outperformer and a solid choice for growth investors [9]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Sco ...

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, particularly in the financial sector, which can lead to exceptional returns. However, identifying such stocks is challenging due to their inherent risks and volatility [1]. Group 1: Growth Stock Identification - The Zacks Growth Style Score system aids in identifying promising growth stocks by analyzing a company's real growth prospects beyond traditional metrics. Masimo (MASI) is currently highlighted as a recommended stock due to its favorable Growth Score and top Zacks Rank [2]. - Stocks with a Growth Score of A or B and a Zacks Rank of 1 (Strong Buy) or 2 (Buy) have been shown to consistently outperform the market [3]. Group 2: Earnings Growth - Earnings growth is crucial for investors, with double-digit growth being particularly desirable as it indicates strong future prospects. Masimo's projected EPS growth for this year is 19.8%, significantly higher than the industry average of 10.8% [4]. Group 3: Cash Flow Growth - Cash flow growth is vital for growth-oriented companies, allowing them to expand without relying on external funding. Masimo's year-over-year cash flow growth stands at 13%, compared to an industry average of -3.3% [5]. - Over the past 3-5 years, Masimo's annualized cash flow growth rate has been 10.7%, exceeding the industry average of 6.7% [6]. Group 4: Earnings Estimate Revisions - Positive trends in earnings estimate revisions correlate strongly with near-term stock price movements. Masimo has experienced upward revisions in current-year earnings estimates, with the Zacks Consensus Estimate increasing by 5.2% over the past month [7][8]. Group 5: Conclusion - Masimo has achieved a Growth Score of A and a Zacks Rank of 1, positioning it favorably for potential outperformance in the growth stock category, making it an attractive option for growth investors [9][10].

Have you been paying attention to shares of Masimo (MASI) ? Shares have been on the move with the stock up 10.7% over the past month. The stock hit a new 52-week high of $194.88 in the previous session. Masimo has gained 15.3% since the start of the year compared to the 6.7% move for the Zacks Medical sector and the 2.2% return for the Zacks Medical - Instruments industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus ...